Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01687413
Other study ID # 201207059
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date January 10, 2013
Est. completion date October 18, 2019

Study information

Verified date November 2020
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial studies the intensity of adjuvant ("helper") therapy required in p16 positive oropharynx cancer patients, who have had all known disease removed surgically by a minimally invasive approach, and who have extracapsular spread in their lymph nodes. Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways. After the surgery, receive either radiation alone, or radiation and weekly cis-platinum during therapy. Patients are then followed for cancer, functional and quality of life outcomes.


Recruitment information / eligibility

Status Terminated
Enrollment 42
Est. completion date October 18, 2019
Est. primary completion date October 18, 2019
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Patient must have histologically confirmed p16 positive squamous cell carcinoma of the oropharynx (OPSCC). - Patient must have undergone transoral resection of their T1-4a oropharynx primary to a negative margin, and a neck dissection(s). - Patient's disease must be pathological N-stage positive. - Patient's disease must show extracapsular spread (ECS) in their nodal metastasis verified by central pathologist's review. - Patients with synchronous primaries are included. - Patients with unknown primaries are included if the diagnosis and resection of a primary site in the oropharynx is made from an endoscopic or robotic surgical procedure(s). - Patients with recent excisional node biopsies/neck dissections are included if material is evaluable for extracapsular spread. - Patient must be = 21 years of age. - ECOG performance status = 2 (Karnofsky =60%). - Patients must have normal organ and marrow function as defined below: - leukocytes =3,000/mcL - absolute neutrophil count =1,500/mcL - platelets =100,000/mcL - total bilirubin <1.5 X upper normal institutional limit - AST(SGOT)/ALT(SGPT) =2.5 X institutional upper limit of normal - creatinine within normal institutional limits OR creatinine clearance =60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal - Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document. Exclusion Criteria: - Patient must not have pathologically N stage negative disease. - Patient must not have outside nodal tissue from previous neck biopsy/neck dissections in which ECS cannot be confirmed or denied. - Patient must not have a true unknown primary in which permanent section results are negative for malignancy in completely excised ipsilateral oropharyngeal tissue (palatine and lingual tonsil). - Patient must not have distant metastatic disease at presentation. - Patient must not have gross residual and/or microscopic disease present after surgery including re-resection(s), per the operative and pathology report. - Patient must not have transoral robotic surgery (TORS) for a T3 or T4 primary tumor. - Patient must not have a history of prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers (for example, carcinoma in situ of the oral cavity, larynx, breast or cervix are all permissible) are permitted even if diagnosed and treated < 3 years ago. - Patient must not have had previous systemic chemotherapy for the study cancer. (Note: prior chemotherapy for a different cancer is allowable). - Patient must not be receiving any other investigational agents. - Patient must not have had any prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields - Patient must not have any life-threatening comorbid illnesses e.g. stroke with major sequelae or myocardial infarction/ unstable angina within the preceding 3 months or psychiatric illness/social situations that would limit compliance with study requirements. - Patient must not be pregnant or breastfeeding. If a woman of childbearing potential, patient must agree to use medically acceptable forms of contraception. Both men and women and members of all races and ethnic groups are eligible for this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Intensity-modulated radiation therapy (IMRT)

Drug:
Cisplatin


Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri
United States Mayo Clinic Scottsdale Scottsdale Arizona

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine BJH Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Disease-free Survival (DFS) 1 year
Primary Locoregional Control Rate of patients with no recurrence at original oropharyngeal site or in the neck nodal basins. Up to 2 years
Secondary Rate of Distant Metastasis Assessed by biopsy or imaging-detected recurrent disease at sites away from the original primary and cervical zone. Up to 2 years
Secondary Disease Specific Survival 1 year
Secondary Number of Complications/Acute Toxicity by Organ Class -Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Approximately 18 weeks
Secondary Change in Quality of Life as Measured by the MD Anderson Dysphagia Inventory Each item is scored on a 5 point Likert scale (strongly disagree, disagree, no opinion, agree, strongly agree). Strongly agree = 1, Disagree = 2, No opinion = 3, Agree = 4, and Strongly Agree = 5
The lower the score the lower the quality of life
Baseline, 1 month, 6 months, 12 months, and 24 months
Secondary Change in Cognitive Function as Measured by Cognitive Failures Questionnaire 25 questions to assess the frequency in which participants experience cognitive failures including forgetfulness, distractibility, and false triggering
Answers range from 0 = never to 4 = very often
The higher the score the worse the cognitive failures the participant has experienced
Baseline, 1 month, 12 months, and 24 months
Secondary Change in Quality of Life as Measured by Neck Dissection Impairment Index (NDII) -The NDII consists of 10 questions; each with a 5 level ordinally scaled response option ranging from "not at all" to "a lot". The response for each item is then scored from 1 to 5, with 5 denoting higher quality of life (Not at all) and 1 being the least (A lot). Baseline, 12 months, and 24 months
Secondary Change in Quality of Life as Measured by University of Michigan Xerostomia Questionnaire It contains 8 questions regarding dryness either during feeding or in the unstimulated state. Participants rate each item from 0 to 10, where 10 indicates the maximum dryness or discomfort due to dryness.
The higher the score the worse the participant's xerostomia
Baseline, 1 month, 6 months, 12 months, and 24 months
Secondary Change in Hearing as Measured by Hearing Handicap Inventory - Adult 11 item questionnaire to identify issues with hearing
Answers are yes = 4, sometimes = 2, and no = 0
The higher the score the more issues the participant has with hearing
Baseline, 1 month, and 12 months
Secondary Change in Quality of Life as Measured by Scale of Subjective Total Taste Acuity 1 question that asks about taste acuity
Answers are 0 = same taste acuity as before treatment; 1 = mild loss of taste acuity, but not inconvenient in daily life; moderate loss of taste acuity, and sometimes inconvenient in daily life; severe loss of taste acuity, and frequently inconvenient in daily life; and 4 = almost complete or complete loss of taste acuity
The higher the score the worse the participant's taste acuity
Baseline, 1 month, 6 months, and 12 months
Secondary Change in Quality of Life as Measured by Speech Handicap Index 31 questions regarding participant's speech and the effects of speech on his/her life
The answers for the first 30 questions range from 0 = never to 4 = always and the answers for the 31st question ranges from 0 = excellent to bad = 4
The higher the score the worse the participant's speech is affecting his/her life
Baseline and 12 months
Secondary Change in Quality of Life as Measured by EORTC QLQ-C30 30 questions designed to assess the quality of life of cancer patients
The first 28 questions have answers that range from 1=not at all to 4 = very much. The higher score indicates a worse quality of life
The last 2 questions have answers that range from 1 = very poor to 7 = excellent. The higher score indicates a better quality of life
Baseline, 1 month, 6 months, 12 months, and 24 months
See also
  Status Clinical Trial Phase
Completed NCT03239834 - Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Recruiting NCT00251381 - Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma. Phase 2
Completed NCT03074110 - Isocapnic Hyperventilation - an Alternative Method N/A
Enrolling by invitation NCT04266093 - Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Recruiting NCT02792322 - Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck N/A
Active, not recruiting NCT00918710 - Human Papillomavirus and Oropharynx Carcinoma N/A
Recruiting NCT05412628 - Investigating the Association Between Microbiota and Esophageal/Oropharyngeal Cancer N/A
Recruiting NCT04124198 - Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma N/A
Completed NCT00721799 - F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients Phase 2
Recruiting NCT00181038 - Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery Phase 3
Terminated NCT04015336 - E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer Phase 2
Withdrawn NCT04044950 - A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer Phase 2
Completed NCT02262247 - A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures N/A
Completed NCT01530997 - De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca Phase 2
Completed NCT03077243 - P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC Phase 2
Completed NCT03010813 - A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery N/A
Terminated NCT02045186 - Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) N/A
Withdrawn NCT02298595 - Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT02281955 - De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study Phase 2
Terminated NCT01525927 - Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity Phase 2